{
    "2021-11-10": [
        [
            {
                "time": "",
                "original_text": "医保谈判第二日：医药股大涨 创新药竞逐",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "医药股",
                        "创新药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国家医保谈判“降价”依然是主旋律，感染药及PD(L)-1新适应症成角逐热点",
                "features": {
                    "keywords": [
                        "国家医保",
                        "降价",
                        "感染药",
                        "PD(L)-1",
                        "适应症"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国谈现场 | PD-1众星捧月，保密工作再升级",
                "features": {
                    "keywords": [
                        "国谈",
                        "PD-1",
                        "保密工作"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "120万元一针抗癌神药首次进入医保谈判！能砍成多少？",
                "features": {
                    "keywords": [
                        "抗癌神药",
                        "医保谈判",
                        "价格谈判"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【行情】医药板块持续走强，沃森生物涨超15%，恒瑞医药、司太立涨超9%，美诺华、君实生物、威尔药业、哈三联、贝达药业等涨幅居前",
                "features": {
                    "keywords": [
                        "医药板块",
                        "沃森生物",
                        "恒瑞医药",
                        "君实生物"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}